ATE45672T1 - Eine pharmazeutische zusammensetzung zum zweck der behandlung einer neurologischen krankheit oder des alterns. - Google Patents
Eine pharmazeutische zusammensetzung zum zweck der behandlung einer neurologischen krankheit oder des alterns.Info
- Publication number
- ATE45672T1 ATE45672T1 AT84303195T AT84303195T ATE45672T1 AT E45672 T1 ATE45672 T1 AT E45672T1 AT 84303195 T AT84303195 T AT 84303195T AT 84303195 T AT84303195 T AT 84303195T AT E45672 T1 ATE45672 T1 AT E45672T1
- Authority
- AT
- Austria
- Prior art keywords
- aging
- pharmaceutical composition
- neurological disease
- treatment
- choline
- Prior art date
Links
- 208000012902 Nervous system disease Diseases 0.000 title abstract 2
- 208000025966 Neurological disease Diseases 0.000 title abstract 2
- 230000032683 aging Effects 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 abstract 3
- 229960001231 choline Drugs 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 2
- 239000002243 precursor Substances 0.000 abstract 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 abstract 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 abstract 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 abstract 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 abstract 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 abstract 1
- 239000004473 Threonine Substances 0.000 abstract 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 abstract 1
- 230000002411 adverse Effects 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 239000002858 neurotransmitter agent Substances 0.000 abstract 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 abstract 1
- 230000002195 synergetic effect Effects 0.000 abstract 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US49520283A | 1983-05-16 | 1983-05-16 | |
| EP84303195A EP0125900B1 (de) | 1983-05-16 | 1984-05-11 | Eine pharmazeutische Zusammensetzung zum Zweck der Behandlung einer neurologischen Krankheit oder des Alterns |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE45672T1 true ATE45672T1 (de) | 1989-09-15 |
Family
ID=23967687
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT84303195T ATE45672T1 (de) | 1983-05-16 | 1984-05-11 | Eine pharmazeutische zusammensetzung zum zweck der behandlung einer neurologischen krankheit oder des alterns. |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP0125900B1 (de) |
| JP (1) | JPS60214734A (de) |
| AT (1) | ATE45672T1 (de) |
| CA (1) | CA1228301A (de) |
| DE (1) | DE3479477D1 (de) |
| ES (1) | ES532873A0 (de) |
| GR (1) | GR79973B (de) |
| IL (1) | IL71819A (de) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2657013B1 (fr) * | 1990-01-18 | 1992-05-15 | Medgenix Group Sa | Composition dietetique a base de polypeptides et acides amines. |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1114295A (en) * | 1977-11-02 | 1981-12-15 | John H. Growdon | Process and composition for treating disorders by administering choline or a compound that dissociates to choline |
| DE2962429D1 (en) * | 1978-04-24 | 1982-05-19 | Massachusetts Inst Technology | A pharmaceutical composition comprising an amino acid for reducing blood serum prolactin levels |
| US4296119A (en) * | 1978-04-24 | 1981-10-20 | Massachusetts Institute Of Technology | Process and composition for reducing blood pressure in animals |
| EP0005058B1 (de) * | 1978-04-24 | 1984-10-17 | Massachusetts Institute Of Technology | Zusammensetzung zur Regulierung des Dopamin- oder Norepinephrin-Spiegels in Neuronen-Synapsen |
| JPS5566512A (en) * | 1978-11-15 | 1980-05-20 | Massachusetts Inst Technology | Method and composition for treating difficulties by administration of choline or choline dissociating compound |
| US4221784A (en) * | 1979-04-05 | 1980-09-09 | Massachusetts Institute Of Technology | Process and composition for treating disorders by administering lecithin |
| DE2915433A1 (de) * | 1979-04-17 | 1980-10-30 | Christensen Plantorgan Werk | Verwendung von physiologisch vertraeglichen methyldonatoren |
| US4397866A (en) * | 1979-05-07 | 1983-08-09 | Massachusetts Institute Of Technology | Process for increasing glycine levels in the brain and spinal cord |
-
1984
- 1984-05-11 AT AT84303195T patent/ATE45672T1/de not_active IP Right Cessation
- 1984-05-11 DE DE8484303195T patent/DE3479477D1/de not_active Expired
- 1984-05-11 EP EP84303195A patent/EP0125900B1/de not_active Expired
- 1984-05-13 IL IL71819A patent/IL71819A/xx not_active IP Right Cessation
- 1984-05-14 JP JP59094739A patent/JPS60214734A/ja active Granted
- 1984-05-15 ES ES532873A patent/ES532873A0/es active Granted
- 1984-05-16 GR GR74742A patent/GR79973B/el unknown
- 1984-05-16 CA CA000454518A patent/CA1228301A/en not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| JPS60214734A (ja) | 1985-10-28 |
| EP0125900A1 (de) | 1984-11-21 |
| JPH0141124B2 (de) | 1989-09-04 |
| IL71819A0 (en) | 1984-09-30 |
| ES8602409A1 (es) | 1985-12-16 |
| IL71819A (en) | 1987-12-31 |
| ES532873A0 (es) | 1985-12-16 |
| EP0125900B1 (de) | 1989-08-23 |
| GR79973B (de) | 1984-10-31 |
| CA1228301A (en) | 1987-10-20 |
| DE3479477D1 (en) | 1989-09-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE68919358D1 (de) | Zusammensetzung zur behandlung der schizophrenie. | |
| DE69132688D1 (de) | Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin | |
| DK46789D0 (da) | 3-indolpyrodruesyrederivater og farmaceutisk anvendelse deraf | |
| DE3684190D1 (de) | Verwendung von tetrahydrobiopterinen zur herstellung eines medikaments zur behandlung von kinderautismus. | |
| DE69230046D1 (de) | 2-Bromomelatonin zur Behandlung von Schlafstörungen | |
| ATE105482T1 (de) | Behandlung von krebs mit somatostatin und mit analogen davon. | |
| DE3856594D1 (de) | Mittel zur behandlung der alzheimer-krankheit | |
| ATE157251T1 (de) | Verwendung von inositoltriphosphat zur behandlung von entzündungen | |
| DE69012261D1 (de) | Verwendung von Sertralin zur Behandlung verfrühter Ejakulation. | |
| DE3583887D1 (de) | Ausruestung fuer die behandlung der osteoporose. | |
| DE69009684D1 (de) | Pharmazeutische Zusammensetzungen zur Behandlung gastrointestinaler Störungen. | |
| DK0502925T3 (da) | præparat til behandling af inflammatoriske tarmlidelser | |
| IT1170214B (it) | Composizione farmaceutica per la cura delle arteriopatie periferiche | |
| DE69316013D1 (de) | Verwendung von phosphinate zur behandlung der osteoporose | |
| FI864246A0 (fi) | N-substituerade 3-piperidin- eller 3-pyridinkarboxylsyror samt deras derivat. | |
| DE3684904D1 (de) | Pharmazeutisches praeparat zur behandlung von stoerungen des fettstoffwechsels (hyperlipoproteinaemien). | |
| ATE45672T1 (de) | Eine pharmazeutische zusammensetzung zum zweck der behandlung einer neurologischen krankheit oder des alterns. | |
| DE3584131D1 (de) | Methode zur behandlung der antidiurese. | |
| DE3879837D1 (de) | Pharmazeutische praeparate zur behandlung von zereberalen psycho-organischen syndromen. | |
| KR880004810A (ko) | 소화성 궤양 치료제 | |
| DE3775854D1 (de) | Arzneimittel zur therapie von durch funktionelle und organische basen verursachten gehirnkrankheiten. | |
| PT98764A (pt) | Processo para a preparacao de composicoes contendo factor de desenvolvimento de insulina 1 completo para o tratamento terapeutico ou profilactico de estado catabolicos | |
| ATE40795T1 (de) | Verwendung eines zerebral und peripher wirkenden antihypoxidotikums. | |
| DE69118847D1 (de) | Verwendung von Heptastigmin zur Behandlung der zerebralen Ictus | |
| DE3786442D1 (de) | Verwendung von follikelreifungshormon zur herstellung eines therapeutischen mittels zur behandlung von neoplasmen von gonadalem ursprung. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification | ||
| REN | Ceased due to non-payment of the annual fee |